Virus-Like Particle (VLP) & Hybrid Platform for CAR Engineering

Online Inquiry

Background Platforms What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides Virus-Like Particle (VLP) & Hybrid Platforms for CAR Engineering to support next-generation in vivo cell therapy development. This platform addresses challenges associated with traditional viral CAR-T approaches, including complex manufacturing processes, integration-related safety concerns, and limited flexibility in immune cell reprogramming. By leveraging engineered VLP systems, optimized particle design, and targeted delivery strategies for mRNA or RNP payloads, Creative Biolabs enables precise, non-integrating CAR engineering approaches to accelerate the development of scalable and adaptable immune cell therapies.

Introduction

Engineered Virus-Like Particles (eVLPs) and hybrid delivery platforms represent a paradigm shift in cell and gene therapy, merging the high transduction efficiency and natural fusogenic entry of viral vectors with the transient, non-integrating safety profiles of non-viral systems. Recent breakthroughs in directed evolution have produced advanced retroviral and lentiviral capsids capable of delivering ribonucleoproteins, Base Editors, and CAR mRNA directly into primary human T cells with multifold improvements in packaging titers and entry kinetics. Surface engineering with targeted scFvs further restricts delivery exclusively to intended immune cell populations, eliminating off-target tissue accumulation and drastically lowering genotoxicity risks.

Fig.1 General introduction to barcoded eVLP evolution workflow. (OA Literature) Fig.1 Review of the barcoded eVLP directed evolution system.¹

Our Platforms

Navigating the transition from traditional ex vivo viral transduction to non-integrating in vivo CAR generation requires specialized capsid development, envelope modification, and payload encapsulation. Creative Biolabs provides end-to-end engineered VLP solutions designed to bypass arduous cell harvesting, expansion, and re-infusion workflows. By harnessing engineered viral capsids devoid of viral genomes, our platform enables direct, transient, and highly target-specific CAR expression inside primary T cells, NK cells, and macrophages.

Our platform addresses critical therapeutic development roadblocks by supplying turnkey deliverables:

High-Titer VLP Assembly Scaffolds: Custom Gag/capsid variants engineered via barcoded directed evolution to maximize packaging density and target cell transduction efficiency.
Targeted Surface Pseudotyping: Envelope engineering utilizing mutated fusogens paired with single-chain variable fragments (scFvs) for cell-type-specific uptake.
Non-Integrating Cargo Loading: Optimized packaging formulations for CAR mRNA, self-amplifying RNA (saRNA), protein RNPs, or transposon DNA cassettes.
Comprehensive Analytical Validation: Full physicochemical characterization, cargo integrity verification, and in vitro/in vivo cytotoxicity profiling.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs delivers a modular technology suite tailored for custom VLP construct design, envelope functionalization, packaging, and functional validation:

Platform of Virus-Like Particle (VLP) & Hybrid Platforms for CAR Engineering. (Creative Biolabs Original)

Our Workflow

Clients provide target CAR/scFv sequences, preferred delivery modalities, and specifications of target immune cell populations for custom project initiation.

Workflow of Virus-Like Particle (VLP) & Hybrid Platforms for CAR Engineering. (Creative Biolabs Original)

Upon project completion, clients receive sterile research-grade functionalized VLP/hybrid particles with validated titers, a full QC report covering particle size, protein purity and encapsulation efficiency, and a functional validation dataset of CAR expression, cell selectivity and cell killing kinetics.

Benefits

Fully Customized VLP & Hybrid Engineering: Custom-tailored capsid architectures, tropism redirection, and payload loading schemes specifically optimized to match your proprietary CAR construct and target cell line.
State-of-the-Art Directed Evolution Platforms: Access to proprietary mutated Gag/capsid variant libraries engineered for ultra-high particle packaging density, structural stability, and superior cell transduction kinetics.
Advanced Dual-Functionalized Surface Engineering: Precision pseudotyping incorporating receptor-blind fusogens and target-specific antibody fragments to guarantee high-specificity in vivo cellular tropism.

FAQs

Q: How do VLPs compare to traditional Lentiviral Vectors (LVVs) for CAR T-cell engineering?

A: VLPs retain the natural fusogenic cell entry mechanisms of viral vectors but lack viral genetic material. This allows them to deliver transient mRNA or RNP payloads without integrating DNA into the host genome, eliminating risks of insertional mutagenesis and long-term CAR-induced T-cell exhaustion.

Q: Can your VLP platform target specific immune cell subsets directly in vivo?

A: Yes. By replacing natural envelope receptor binding with receptor-blind fusogens co-expressed with cell-specific antibodies or scFvs (such as anti-CD3 or anti-CD56), our VLPs selectively bind and transduce targeted T cells or NK cells while avoiding non-specific clearance by off-target organs like the liver.

Q: What types of CAR payloads can be packaged inside Creative Biolabs' engineered VLPs?

A: Our packaging platform supports single- and multi-cistronic CAR mRNA, saRNA, pre-assembled ribonucleoprotein (RNP) complexes, and non-viral DNA transposon systems.

Partner with Us

Creative Biolabs offers complete, high-performance Virus-Like Particle (VLP) & Hybrid Platforms for CAR Engineering, enabling biopharmaceutical partners to transition toward safer, scalable, non-integrating in vivo cell therapies. From custom directed evolution Gag scaffolds and receptor-blind envelope targeting to full functional validation, our technical team provides end-to-end expertise tailored to your specific pipeline goals. Aiming to advance your next-generation CAR vector development program? Consult our seasoned scientific team to define your project parameters, obtain technical documents, or acquire a personalized quotation. Connect with us for additional information and in-depth project communication.

Reference

Raguram A, An M, Chen PZ, Liu DR. Directed evolution of engineered virus-like particles with improved production and transduction efficiencies. Nat Biotechnol. 2025 Oct;43(10):1635-1647. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41587-024-02467-x

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.